These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30711384)

  • 21. Microenvironmental characteristics and physiology of biofilms in chronic infections of CF patients are strongly affected by the host immune response.
    Jensen PØ; Kolpen M; Kragh KN; Kühl M
    APMIS; 2017 Apr; 125(4):276-288. PubMed ID: 28407427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
    Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C
    J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of pH on the antimicrobial susceptibility of planktonic and biofilm-grown clinical Pseudomonas aeruginosa isolates.
    Moriarty TF; Elborn JS; Tunney MM
    Br J Biomed Sci; 2007; 64(3):101-4. PubMed ID: 17910277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR.
    Young RL; Malcolm KC; Kret JE; Caceres SM; Poch KR; Nichols DP; Taylor-Cousar JL; Saavedra MT; Randell SH; Vasil ML; Burns JL; Moskowitz SM; Nick JA
    PLoS One; 2011; 6(9):e23637. PubMed ID: 21909403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modelling of ciprofloxacin killing enhanced by hyperbaric oxygen treatment in Pseudomonas aeruginosa PAO1 biofilms.
    Gade PAV; Olsen TB; Jensen PØ; Kolpen M; Høiby N; Henneberg KÅ; Sams T
    PLoS One; 2018; 13(6):e0198909. PubMed ID: 29902223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
    Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
    Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperoxia prolongs the aminoglycoside-induced postantibiotic effect in Pseudomonas aeruginosa.
    Park MK; Muhvich KH; Myers RA; Marzella L
    Antimicrob Agents Chemother; 1991 Apr; 35(4):691-5. PubMed ID: 1906262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment.
    MacLeod DL; Nelson LE; Shawar RM; Lin BB; Lockwood LG; Dirk JE; Miller GH; Burns JL; Garber RL
    J Infect Dis; 2000 Mar; 181(3):1180-4. PubMed ID: 10720551
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Orazi G; O'Toole GA
    mBio; 2017 Jul; 8(4):. PubMed ID: 28720732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth.
    Høiby N; Krogh Johansen H; Moser C; Song Z; Ciofu O; Kharazmi A
    Microbes Infect; 2001 Jan; 3(1):23-35. PubMed ID: 11226851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
    Shawar RM; MacLeod DL; Garber RL; Burns JL; Stapp JR; Clausen CR; Tanaka SK
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2877-80. PubMed ID: 10582875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Li Z; Barnaby R; Nymon A; Roche C; Koeppen K; Ashare A; Hogan DA; Gerber SA; Taatjes DJ; Hampton TH; Stanton BA
    Am J Physiol Lung Cell Mol Physiol; 2024 May; 326(5):L574-L588. PubMed ID: 38440830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.
    Wiesemann HG; Steinkamp G; Ratjen F; Bauernfeind A; Przyklenk B; Döring G; von der Hardt H
    Pediatr Pulmonol; 1998 Feb; 25(2):88-92. PubMed ID: 9516091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.
    Valenza G; Radike K; Schoen C; Horn S; Oesterlein A; Frosch M; Abele-Horn M; Hebestreit H
    Scand J Infect Dis; 2010 Dec; 42(11-12):885-9. PubMed ID: 20735333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa.
    Wu YL; Scott EM; Po AL; Tariq VN
    J Antimicrob Chemother; 1999 Sep; 44(3):389-92. PubMed ID: 10511408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Azithromycin potentiates avian IgY effect against Pseudomonas aeruginosa in a murine pulmonary infection model.
    Thomsen K; Christophersen L; Lerche CJ; Holmgaard DB; Calum H; Høiby N; Moser C
    Int J Antimicrob Agents; 2021 Jan; 57(1):106213. PubMed ID: 33256950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphonuclear leukocytes restrict growth of Pseudomonas aeruginosa in the lungs of cystic fibrosis patients.
    Kragh KN; Alhede M; Jensen PØ; Moser C; Scheike T; Jacobsen CS; Seier Poulsen S; Eickhardt-Sørensen SR; Trøstrup H; Christoffersen L; Hougen HP; Rickelt LF; Kühl M; Høiby N; Bjarnsholt T
    Infect Immun; 2014 Nov; 82(11):4477-86. PubMed ID: 25114118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.